Patent classifications
C07F9/78
Selective Targeting of Procoagulant Platelets
The invention relates to a process for identifying procoagulant platelets both in vitro and in vivo, and the identification of compounds which selectively inhibit formation of procoagulant platelets.
Selective Targeting of Procoagulant Platelets
The invention relates to a process for identifying procoagulant platelets both in vitro and in vivo, and the identification of compounds which selectively inhibit formation of procoagulant platelets.
CONJUGATES AND THEIR USE AS IMAGING AGENTS
The invention relates to compounds according to Formula (I) wherein A is —As(OH).sub.2 or an arsenoxide equivalent group; each of R1, R.sub.2, R.sub.3 and R.sub.4 is independently selected from H, X, OH, NH.sub.2, CO, SCN, —CH.sub.2NH, —NHCOCH.sub.3, —NHCOCH.sub.2X or NO, and X is a halogen; R.sub.5 is —NHCH.sub.2COOH, OH or OR6, wherein R.sub.6 is a C.sub.1-5 straight or branched alkyl group; and Z is a radioisotope with a half-life of less than 4 days, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to diagnostic methods utilizing said compounds.
CONJUGATES AND THEIR USE AS IMAGING AGENTS
The invention relates to compounds according to Formula (I) wherein A is —As(OH).sub.2 or an arsenoxide equivalent group; each of R1, R.sub.2, R.sub.3 and R.sub.4 is independently selected from H, X, OH, NH.sub.2, CO, SCN, —CH.sub.2NH, —NHCOCH.sub.3, —NHCOCH.sub.2X or NO, and X is a halogen; R.sub.5 is —NHCH.sub.2COOH, OH or OR6, wherein R.sub.6 is a C.sub.1-5 straight or branched alkyl group; and Z is a radioisotope with a half-life of less than 4 days, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to diagnostic methods utilizing said compounds.
ANTI-CANCER AGENT
An anti-cancer agent is provided comprising a tumour homing peptide having, or having been modified to present, two cysteine residues, with an arsenic atom between, such that the tumour homing peptide cyclises to give an arsenic-containing anti-cancer agent. This allows for selection of an appropriate tumour homing peptide for treatment of a given cancer whereby the subsequent agent provides for a more targeted delivery of arsenic to the tumour microenvironment.
CONJUGATES AND THEIR USE AS IMAGING AGENTS
The invention relates to compounds according to Formula (I):
##STR00001##
wherein A is As(OH).sub.2 or an arsenoxide equivalent group; each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is independently selected from H, X, OH, NH.sub.2, CO, SCN, CH.sub.2NH, NHCOCH.sub.3, NHCOCH.sub.2X or NO, and X is a halogen; R.sub.5 is NHCH.sub.2COOH, OH or OR.sub.6, wherein R.sub.6 is a C.sub.1-5 straight or branched alkyl group; and Z is a radioisotope with a half-life of less than 4 days, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to diagnostic methods utilizing said compounds.
CONJUGATES AND THEIR USE AS IMAGING AGENTS
The invention relates to compounds according to Formula (I):
##STR00001##
wherein A is As(OH).sub.2 or an arsenoxide equivalent group; each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is independently selected from H, X, OH, NH.sub.2, CO, SCN, CH.sub.2NH, NHCOCH.sub.3, NHCOCH.sub.2X or NO, and X is a halogen; R.sub.5 is NHCH.sub.2COOH, OH or OR.sub.6, wherein R.sub.6 is a C.sub.1-5 straight or branched alkyl group; and Z is a radioisotope with a half-life of less than 4 days, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to diagnostic methods utilizing said compounds.
Organic Light Emitting Device
The present specification relates to an organic light emitting device including an anode, a first organic material layer including a compound of Chemical Formula 1, a second organic material layer including a compound of Chemical Formula 2, a light emitting layer and a cathode.
Conjugates and their use as imaging agents
The invention relates to compounds according to Formula (I): ##STR00001##
wherein A is As(OH).sub.2 or an arsenoxide equivalent group; each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is independently selected from H, X, OH, NH.sub.2, CO, SCN, CH.sub.2NH, NHCOCH.sub.3, NHCOCH.sub.2X or NO, and X is a halogen; R.sub.5 is NHCH.sub.2COOH, OH or OR.sub.6, wherein R.sub.6 is a C.sub.1-5 straight or branched alkyl group; and Z is a radioisotope with a half-life of less than 4 days, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to diagnostic methods utilizing said compounds.
Conjugates and their use as imaging agents
The invention relates to compounds according to Formula (I): ##STR00001##
wherein A is As(OH).sub.2 or an arsenoxide equivalent group; each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is independently selected from H, X, OH, NH.sub.2, CO, SCN, CH.sub.2NH, NHCOCH.sub.3, NHCOCH.sub.2X or NO, and X is a halogen; R.sub.5 is NHCH.sub.2COOH, OH or OR.sub.6, wherein R.sub.6 is a C.sub.1-5 straight or branched alkyl group; and Z is a radioisotope with a half-life of less than 4 days, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to diagnostic methods utilizing said compounds.